# Ligand Completes $739M XOMA Deal

> Ligand's royalty revenue jumps 51% after $739M acquisition of XOMA.
- Title: Ligand Completes $739M XOMA Deal · Dealroom | Shortify
- Summary: Ligand's royalty revenue jumps 51% after $739M acquisition of XOMA. Ligand Pharmaceuticals completed a $739 million deal with XOMA, boosting royalty revenue…
- Keywords: ligand, xoma, royalty revenue, biopharmaceutical, acquisition, filspari, travere therapeutics, us approval, focal segmental glomerulosclerosis, Dealroom
- Source: Dealroom — https://dealroom.co/news/169800-ligand-completes-739m-xoma-deal-as-royalty-revenue-jumps-51
- Published: 2026-11-05T00:13:02+00:00
- Read time: 1 min
- Topics: ligand, xoma, royalty revenue, biopharmaceutical, acquisition, filspari, travere therapeutics, us approval, focal segmental glomerulosclerosis, startups, business
## Deal Completion
Ligand Pharmaceuticals completed its $739 million acquisition of XOMA in July.
## Royalty Revenue Growth
Third-quarter royalty revenue rose 51% year over year to $70.3 million.
## Filspari Impact
Filspari generated $16.8 million in Q3 royalties, up 85% year over year.
## Key takeaway

Ligand Pharmaceuticals completed a $739 million deal with XOMA, boosting royalty revenue by 51% year over year to $70.3 million.